Factors associated with improvement of fasting plasma glucose level by mealtime dosing of a rapid-acting insulin analog in type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 75, Issue 3, 2007, Pages 278-284

  Takamura, Toshinari ^a   Sakurai, Masaru ^a   Nakamura, Masumi ^a   Shimizu, Akiko ^a   Ota, Tsuguhito ^a   Misu, Hirofumi ^a   Takeshita, Yumie ^a   Tsuchiyama, Naomi ^a   Kurita, Seiichiro ^a   Ando, Hitoshi ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Arginine; Basal insulin replacement; Glucagon; Mealtime dosing; Rapid acting insulin analog; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN LISPRO;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; JAPAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY;

AGED; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; EATING; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED;

EID: 33846109818     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.07.019     Document Type: Article

References (34)

1. Hara H., Egusa G., Yamakido M., and Kawate R. The high prevalence of diabetes mellitus and hyperinsulinemia among the Japanese-Americans living in Hawaii and Los Angeles. Diab. Res. Clin. Pract. 24 Suppl. (1994) S37-S42
2. Jensen C.C., Cnop M., Hull R.L., Fujimoto W.Y., and Kahn S.E. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. Diabetes 51 (2002) 2170-2178
3. Kadowaki T., Miyake Y., Hagura R., et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 26 (1984) 44-49
4. Kahn S.E. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J. Clin. Endocrinol. Metab. 86 (2001) 4047-4058
5. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., and Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
6. Robertson R.P., Olson L.K., and Zhang H.J. Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes 43 (1994) 1085-1089
7. Robertson R.P., Harmon J., Tran P.O., Tanaka Y., and Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52 (2003) 581-587
8. Feinglos M.N., Thacker C.H., English J., Bethel M.A., and Lane J.D. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diab. Care 20 (1997) 1539-1542
9. Saloranta C., Hershon K., Ball M., Dickinson S., and Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J. Clin. Endocrinol. Metab. 87 (2002) 4171-4176
10. Ogawa S., Takeuchi K., and Ito S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes. Diab. Obes. Metab. 6 (2004) 384-390
11. Galloway J.A., and Chance R.E. Improving insulin therapy: achievements and challenges. Horm. Metab. Res. 26 (1994) 591-598
12. Anderson Jr. J.H., Brunelle R.L., Koivisto V.A., Trautmann M.E., Vignati L., DiMarchi R., and Multicenter Insulin Lispro Study Group. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin. Ther. 19 (1997) 62-72
13. Del Prato S. In search of normoglycaemia in diabetes: controlling postprandial glucose. Int. J. Obes. Relat. Metab. Disord. 26 Suppl. 3 (2002) S9-S17
14. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diab. Care 26 (Suppl. 1) (2003) S5-S20.
15. Japan Diabetes Society. Diabetes Treatment Guide, 2002-2003 (2002), Bunkodo, Tokyo
16. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
17. DECODE Study Group, The European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria. Arch. Intern. Med. 161 (2001) 397-405
18. 1c. Diab. Care 23 (2000) 1236-1241
19. 1c. Diab. Care 26 (2003) 881-885
20. 2+ concentration. J. Biol. Chem. 273 (1998) 33501-33507
21. Maedler K., Carr R.D., Bosco D., Zuellig R.A., Berney T., and Donath M.Y. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J. Clin. Endocrinol. Metab. 90 (2005) 501-506
22. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am. J. Med. 113 Suppl. 6A (2002) 3S-11S
23. Proietto J. Mechanisms of insulin resistance caused by nutrient toxicity. Hepatol. Res. 33 (2005) 87-91
24. Hawkins M., and Rossetti L. Insulin resistance and its role in the pathogenesis of type 2 diabetes. In: Kahn R.C., Weir G.C., King G.L., Jacobson A.M., Moses A.C., and Smith R.J. (Eds). Joslin's Diabetes Mellitus (2005), Lippincott Williams & Wilkins, Philadelphia 425-448
25. Zhao H., Yakar S., Gavrilova O., et al. Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes. Diabetes 53 (2004) 2901-2909
26. Henquin J.-C. Cell biology of insulin secretion. In: Kahn R.C., Weir G.C., King G.L., Jacobson A.M., moses A.C., and Smith R.J. (Eds). Joslin's Diabetes Mellitus (2005), Lippincott Williams & Wilkins, Philadelphia 83-107
27. Faber O.K., and Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 26 (1977) 605-610
28. Hendriksen C., Faber O.K., Drejer J., and Binder C. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-petide response to intravenous glucagon. Diabetologia 13 (1977) 615-619
29. Madsbad S., Krarup T., McNair P., et al. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med. Scand. 210 (1981) 153-156
30. Robertson R.P. Consequences on beta-cell function and reserve after long-term pancreas transplantation. Diabetes 53 (2004) 633-644
31. Ahren B., and Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur. J. Endocrinol. 150 (2004) 97-104
32. Kawamori R., Shichiri M., Kikuchi M., Yamasaki Y., and Abe H. Perfect normalization of excessive glucagon responses to intravenous arginine in human diabetes mellitus with the artificial beta-cell. Diabetes 29 (1980) 762-765
33. Hamaguchi T., Fukushima H., Uehara M., et al. Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells. Diabetologia 34 (1991) 801-806
34. Xu E., Kumar M., Zhang Y., et al. Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell. Metab. 3 (2006) 47-58